Form 4: Nuvalent CMO Sells Shares, Receives Equity Awards

Nuvalent's Chief Medical Officer, Christopher Durant Turner, reported sales of Class A Common Stock under a 10b5-1 plan and received new equity awards.

Summary

• Christopher Durant Turner, Chief Medical Officer of Nuvalent, Inc. (NUVL), reported transactions involving Class A Common Stock.
• On January 5, 2026, he disposed of 871 shares at a weighted average price of $96.06, 1,119 shares at $96.85, 1,929 shares at $97.96, and 317 shares at $98.52.
• On January 6, 2026, he disposed of 1,321 shares at $96.75, 1,635 shares at $97.33, and 225 shares at $98.40.
• These sales, totaling 7,417 shares, were executed pursuant to a Rule 10b5-1 sell-to-cover instruction letter dated December 6, 2023, to satisfy tax withholding obligations from vesting equity awards.
• On January 7, 2026, he acquired 17,500 shares of Class A Common Stock through restricted stock units (RSUs) at a price of $0.00. These RSUs vest in three equal annual installments starting January 7, 2026.
• Also on January 7, 2026, he acquired stock options to buy 17,500 shares of Class A Common Stock at an exercise price of $106.82. These options vest over four years in equal monthly installments starting January 7, 2026, and expire on January 7, 2036.
• Following these transactions, Christopher Durant Turner beneficially owns 72,630 shares of Class A Common Stock directly and 17,500 derivative securities (stock options) directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including pre-planned sales for tax purposes and the grant of new equity awards. This is a neutral event, reflecting standard executive compensation and tax management practices, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The Chief Medical Officer received significant new equity awards, including 17,500 restricted stock units and options for 17,500 shares, indicating continued long-term incentive and alignment with shareholder interests.
• The sales were pre-planned under a Rule 10b5-1 plan, specifically for tax withholding, suggesting a routine and non-discretionary transaction rather than a discretionary sale due to lack of confidence.
• The vesting schedules for both RSUs and stock options are tied to continued service, reinforcing management's commitment to the company.

Negatives

• The Chief Medical Officer disposed of 7,417 shares of Class A Common Stock over two days.

Future Outlook

The acquired restricted stock units (RSUs) will vest in three equal annual installments following January 7, 2026, contingent on continued service. The stock options will vest over four years in equal monthly installments following January 7, 2026, also subject to continued service.

Industry Context

This Form 4 filing reports routine insider transactions for Nuvalent, Inc. and does not provide broader industry context. Such filings are common across all industries for publicly traded companies when executives receive or exercise equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The report provides transparency regarding executive stock transactions, which is generally positive for investor confidence. The sales were for tax purposes, mitigating concerns about discretionary selling. The new equity awards align management's long-term interests with shareholders.
• Employees: The report details executive compensation, which can set a precedent or context for broader employee equity programs, though it doesn't directly impact general employees.

Next Steps

• RSUs will vest in three equal annual installments following January 7, 2026, subject to continued service.
• Stock options will vest over four years in equal monthly installments following January 7, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically pre-planned sales to cover tax obligations and the grant of new equity awards as part of executive compensation. These events are standard for publicly traded companies and do not indicate any fundamental change in the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing. The new equity awards reinforce management's long-term alignment with shareholder value.

Keywords

Nuvalent, NUVL, Insider Trading, Form 4, Equity Awards, Stock Options, RSUs, Chief Medical Officer, Christopher Durant Turner, 10b5-1 Plan